Mesoblast

Mesoblast Dividend Coverage

Dividend Coverage Ratio of Mesoblast (MESO) as of Oct 21, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of Mesoblast is 2026 - . Dividend Coverage Ratio of Mesoblast was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd, based in Melbourne, Australia, develops regenerative medicine products using mesenchymal lineage cells. The company focuses on clinical-stage therapies such as Remestemcel-L for inflammatory conditions including graft versus host disease and inflammatory bowel disease, and MPC-300-IV for rheumatoid arthritis. It operates in Australia, the US, Singapore, and Switzerland with 81 employees and is listed on the stock exchange since 2015. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Mesoblast since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Mesoblast historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Mesoblast

All Key Metrics — Mesoblast